PET在霍奇金淋巴瘤一线治疗中的作用
本综述聚焦3期研究,阐述PET-CT标准化用于霍奇金淋巴瘤分期、中期和终期疗效评估后管理策略的变化,指出PET适应策略改善了总生存,但最佳策略仍存争议。
要点
- PET-CT标准化用于霍奇金淋巴瘤分期、中期及终期疗效评估。
- PET适应策略使总生存获得重大改善。
- 最佳治疗策略仍存争议,需个体化决策。
核心结论
- PET适应策略使霍奇金淋巴瘤总生存获得重大改善,但最佳策略仍存争议。
研究设计与样本
- 本综述主要聚焦3期研究,梳理PET-CT标准化对霍奇金淋巴瘤管理的影响。
主要发现
- PET-CT标准化用于霍奇金淋巴瘤分期、中期和终期疗效评估。
- PET适应策略促进了总生存的重大改善。
临床怎么用
- 治疗血液科医生可依据PET-CT标准化评估结果制定患者个体化策略。
局限性
- 最佳策略仍存争议,临床意见分化。
- 未满足需求包括生育力保护、心血管健康、生存者问题及老年患者治愈率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PET using 18F-fluorodeoxyglucose is central to the management of patients with Hodgkin lymphoma, and PET-adapted strategies have facilitated major improvements in overall survival. Although unmet needs include addressing fertility preservation, cardiovascular health, and survivorship issues, along with a need for better cure rates in the older patient, the improved survival of most patients with Hodgkin lymphoma globally is a triumph of the complementary approaches and collaboration of many cooperative groups in the study of PET-guided therapy. The optimal strategy for this highly curable lymphoma, however, remains a topic of intense discussion and polarises opinion among clinicians. In this Review, we seek not to debate the many controversies that exist but to better inform the treating haematologist to assist in navigating a patient-specific approach. Focusing primarily on phase 3 studies, we chart the changes in management based on the most relevant technological advance in the past decade, the standardisation of PET-CT for staging, interim, and end-of-treatment response assessment of Hodgkin lymphoma.
引用
- Trotman J, Barrington SF. The role of PET in first-line treatment of Hodgkin lymphoma. Lancet Haematol. 2020. PMID: 33357485. doi:10.1016/S2352-3026(20)30357-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。